Plasma Fractionation Market Insights, 2018-2026

Plasma Fractionation Market (Product Type - Immunoglobulin, Coagulation Factor Concentrates, Albumin, Protease Inhibitors; Applications - Neurology, Immunology, Hematology, Critical Care, Pulmonology; End use - Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Global Plasma Fractionation Market - Snapshot

Plasma fractionation is the first process for large-scale protein purification, which was developed about 60 years ago by Cohn and co-workers. Currently, therapeutically important proteins are human serum albumin (HSA), immunoglobulin (IG), coagulation factor VIII, and protease inhibitors. Presently, plasma protein fractionation is, by far, the largest segment in the global therapeutic protein manufacture industry. Rising indications and therapeutic usage of plasma-derived proteins is an important factor that is expected to boost the plasma fractionation market during the forecast period. The global plasma fractionation market was valued at US$ 18,420.00 Mn in 2017 and is anticipated to reach US$ 33,763.10 Mn by 2026, expanding at a CAGR of 7.1% from 2018 to 2026. Rise in the geriatric population and the demand for plasma proteins is anticipated to drive the demand for plasma fractionation during the forecast period.

plasma fractionation market

Increase in demand for plasma proteins, rise in investment in innovation, and increase in prevalence of rare diseases across the world are key factors that are projected to propel the global plasma fractionation market. The plasma fractionation industry has been investing in research and development of new plasma proteins therapies (e.g.: Ceruloplasmin, IgA, Plasmin) leading to innovative treatments for the benefits of patients. For instance, in March 2016, Grifols announced that it would invest US$ 360 Mn to expand its production capabilities for plasma-derived therapies. The investment is expected to increase the capacity of plasma fractionation and purification of several proteins. Moreover, rise in investments in innovation leads to technological advancements in efficient and cost-effective procedures for fractionating proteins from plasma, which in turn boost the plasma fractionation market. However, rising market penetration by recombinant factors and stringent regulations and reimbursement issues are major factors restraining the global plasma fractionation market.

The global plasma fractionation market has been segmented based on product type, application, end-user and region. In terms of product type, the global plasma fractionation market has been classified into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. The immunoglobulin segment has been further sub-segmented into intravenous immunoglobulin and subcutaneous immunoglobulin. The coagulation factor concentrates segment factor VIII, factor IX, factor XIII, prothrombin complex concentrate, Von Willebrand factor, and fibrinogen concentrates. In terms of application, the global plasma fractionation market has been classified into neurology, immunology, hematology, critical care, pulmonology, and other applications. In terms of end-user, the global market has been segregated into hospitals and clinics, clinical research laboratories, and academic institutes. In terms of region, the global plasma fractionation market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Based on product type, the immunoglobulin segment dominates the global plasma fractionation market. The segment dominates the market, owing to the rise prevalence of autoimmune diseases such as primary humoral immunodeficiency (PIDD), multiple sclerosis, immune thrombocytopenia purpura (ITP), autoimmune hemolytic anemia, and Kawasaki syndrome. According to the Immune Deficiency Foundation (IDF), approximately 83 people per 100,000 in the U.S. suffer from primary immunodeficiency, and there are more than 5 million undiagnosed cases in the U.S. alone each year. Hence, these factors boost the rate of adoption of immunoglobulins, which in turn boosts the market. The albumin segment is also anticipated to expand at a steady pace during the forecast period. Wide applications of human albumin as a drug formulation agent, vaccine ingredient, sealant in surgeries, and coating for medical devices and equipment are likely to propel the segment in the next few years.

Based on application, the neurology segment dominates the global plasma fractionation market. Rise in number of neurological disorders augments the segment. World Health Organization data suggest that neurological and psychiatric disorders are an important and growing cause of morbidity. The magnitude and burden of mental, neurological, and behavioral disorders is huge, affecting more than 450 million people globally per year.

Based on end-user, the hospital and clinics segment dominates the global plasma fractionation market. Hospitals are witnessing robust expansion, propelled by joint ventures, acquisitions, and provision of one-stop-shop services under one roof for various medical needs.

In terms of region, North America and Europe accounted for a combined market share of 60% in 2017. High prevalence of infectious diseases such as cholera, influenza, and syphilis in North America fuelled the demand for utilization of plasma fractionation. Likewise, Europe accounted for a prominent share, and followed North America in terms of share, of the total global market, due to the presence of a large geriatric population that is more prone to infections. Asia Pacific is regarded as an emerging market for plasma fractionation owing to the presence of large patient population, poor sanitization, and low awareness about plasma fractionation products among the people in the region.

Major players operating in the global plasma fractionation market include CSL Limited, Shire plc, Sanquin, Biotest AG., GRIFOLS, Baxter International Inc., Kedrion, Octapharma and China Biologic Products Holdings, Inc. These players adopt organic and in-organic growth strategies in order to expand product offerings, strengthen geographical reach, increase customer base, and capture market share.

The global plasma fractionation market has been segmented as follows:

by Product Type

  • Immunoglobulin 
    • Intravenous Immunoglobulin
    • Subcutaneous Immunoglobulin
  • Coagulation Factor Concentrates
    • Factor VIII 
    • Factor IX 
    • Factor XIII 
    • Prothrombin Complex Concentrates
    • Von Willebrand Factor (VWF) 
    • Fibrinogen Concentrates 
  • Albumin 
  • Protease Inhibitors 
  • Other Plasma Products

by Application

  • Neurology
  • Immunology
  • Hematology
  • Critical Care
  • Pulmonology
  • Other Applications

by End-user

  • Hospitals and Clinics
  • Clinical Research Laboratories
  • Academic Institutes

by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • China
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Rest of Middle East & Africa

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Plasma Fractionation Market

    4. Market Overview
         4.1. Introduction
         4.2. Overview
         4.3. Market Dynamics
                4.3.1. Drivers
                4.3.2. Restraints
                4.3.3. Opportunities
         4.4. Global Plasma Fractionation Market Analysis and Forecast, 2016–2026

    5. Market Outlook
         5.1. Regional Distribution of Fractionation Plants
         5.2. Regional Distribution of Fractionation Throughput
         5.3. Worldwide IVIG Unit Sales by Region
         5.4. Worldwide Albumin Unit Sales by Region
         5.5. Plasma Proteins and their Clinical Significance
         5.6. Value Chain Analysis

    6. Global Plasma Fractionation Market Analysis and Forecast, by Product Type
         6.1. Introduction & Definition
         6.2. Key Findings / Developments
         6.3. Global Plasma Fractionation Market Value Forecast, by Product Type, 2016–2026
                6.3.1. Immunoglobulin
                         6.3.1.1. Intravenous Immunoglobulin
                         6.3.1.2. Subcutaneous Immunoglobulin
                6.3.2. Coagulation Factor Concentrates
                         6.3.2.1. Factor VIII
                         6.3.2.2. Factor IX
                         6.3.2.3. Factor XIII
                         6.3.2.4. Prothrombin Complex Concentrates
                         6.3.2.5. Von Willebrand Factor (VWF)
                         6.3.2.6. Fibrinogen Concentrates
                6.3.3. Albumin
                6.3.4. Protease Inhibitors
                6.3.5. Other Plasma Products
         6.6. Global Plasma Fractionation Market Attractiveness, by Product Type

    7. Global Plasma Fractionation Market Analysis and Forecast, by Application
         7.1. Introduction & Definition
         7.2. Global Plasma Fractionation Market Value Forecast, by Application, 2016–2026
                7.2.1. Neurology
                7.2.2. Immunology
                7.2.3. Hematology
                7.2.4. Critical Care
                7.2.5. Pulmonology
                7.2.6. Other Applications
         7.7. Global Plasma Fractionation Market Attractiveness, by Product

    8. Global Plasma Fractionation Market Analysis and Forecast, by End-user
         8.1. Introduction & Definition
         8.2. Global Plasma Fractionation Market Value Forecast, by End-user, 2016–2026
                8.2.1. Hospitals and Clinics
                8.2.2. Clinical Research Laboratories
                8.2.3. Academic Institutes

    9. Global Plasma Fractionation Market Analysis and Forecast, by Region
         9.1. Global Market Scenario
         9.2. Global Plasma Fractionation Market Value Forecast, by Region
                9.2.1. North America
                9.2.2. Europe
                9.2.3. Asia Pacific
                9.2.4. Latin America
                9.2.5. Middle East & Africa
         9.3. Global Plasma Fractionation Market Attractiveness, by Region

    10. North America Plasma Fractionation Market Analysis and Forecast
         10.1. Introduction
         10.2. North America Plasma Fractionation Market Value Forecast, by Product Type, 2016–2026
                10.2.1. Immunoglobulin
                         10.2.1.1. Intravenous Immunoglobulin
                         10.2.1.2. Subcutaneous Immunoglobulin
                10.2.2. Coagulation Factor Concentrates
                         10.2.2.1. Factor VIII
                         10.2.2.2. Factor IX
                         10.2.2.3. Factor XIII
                         10.2.2.4. Prothrombin Complex Concentrates
                         10.2.2.5. Von Willebrand Factor (VWF)
                         10.2.2.6. Fibrinogen Concentrates
                10.2.3. Albumin
                10.2.4. Protease Inhibitors
                10.2.5. Other Plasma Products
         10.3. North America Plasma Fractionation Market Value Forecast, by Application, 2016–2026
                10.3.1. Neurology
                10.3.2. Immunology
                10.3.3. Hematology
                10.3.4. Critical Care
                10.3.5. Pulmonology
                10.3.6. Other Applications
         10.4. North America Plasma Fractionation Market Value Forecast, by End-user, 2016–2026
                10.4.1. Hospitals and Clinics
                10.4.2. Clinical Research Laboratories
                10.4.3. Academic Institutes
         10.5. North America Plasma Fractionation Market Value Forecast, by Country, 2016–2026
                10.5.1. U.S.
                10.5.2. Canada
         10.6. North America Plasma Fractionation Market Attractiveness Analysis
                10.6.1. By Product
                10.6.2. By Application
                10.6.3. By End-user
                10.6.4. Country

    11. Europe Plasma Fractionation Market Analysis and Forecast
         11.1. Introduction
         11.2. Europe Plasma Fractionation Market Value Forecast, by Product Type, 2016–2026
                11.2.1. Immunoglobulin
                         11.2.1.1. Intravenous Immunoglobulin
                         11.2.1.2. Subcutaneous Immunoglobulin
                11.2.2. Coagulation Factor Concentrates
                         11.2.2.1. Factor VIII
                         11.2.2.2. Factor IX
                         11.2.2.3. Factor XIII
                         11.2.2.4. Prothrombin Complex Concentrates
                         11.2.2.5. Von Willebrand Factor (VWF)
                         11.2.2.6. Fibrinogen Concentrates
                11.2.3. Albumin
                11.2.4. Protease Inhibitors
                11.2.5. Other Plasma Products
         11.3. Europe Plasma Fractionation Market Value Forecast, by Application, 2016–2026
                11.3.1. Neurology
                11.3.2. Immunology
                11.3.3. Hematology
                11.3.4. Critical Care
                11.3.5. Pulmonology
                11.3.6. Other Applications
         11.4. Europe Plasma Fractionation Market Value Forecast, by End-user, 2016–2026
                10.4.1. Hospitals and Clinics
                10.4.2. Clinical Research Laboratories
                10.4.3. Academic Institutes
         11.5. Europe Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2016–2026
                11.5.1. Germany
                11.5.2. U.K.
                11.5.3. France
                11.5.4. Spain
                11.5.5. Italy
                11.5.6. Rest of Europe
         11.6. Europe Plasma Fractionation Market Attractiveness Analysis
                11.6.1. By Product
                11.6.2. By Application
                11.6.3. By End-user
                11.6.4. Country

    12. Asia Pacific Plasma Fractionation Market Analysis and Forecast
         12.1. Introduction
         12.2. Asia Pacific Plasma Fractionation Market Value Forecast, by Product Type, 2016–2026
                12.2.1. Immunoglobulin
                         12.2.1.1. Intravenous Immunoglobulin
                         12.2.1.2. Subcutaneous Immunoglobulin
                12.2.2. Coagulation Factor Concentrates
                         12.2.2.1. Factor VIII
                         12.2.2.2. Factor IX
                         12.2.2.3. Factor XIII
                         12.2.2.4. Prothrombin Complex Concentrates
                         12.2.2.5. Von Willebrand Factor (VWF)
                         12.2.2.6. Fibrinogen Concentrates
                12.2.3. Albumin
                12.2.4. Protease Inhibitors
                12.2.5. Other Plasma Products
         12.3. Asia Pacific Plasma Fractionation Market Value Forecast, by Application, 2016–2026
                12.3.1. Neurology
                12.3.2. Immunology
                12.3.3. Hematology
                12.3.4. Critical Care
                12.3.5. Pulmonology
                12.3.6. Other Applications
         12.4. Asia Pacific Plasma Fractionation Market Value Forecast, by End-user, 2016–2026
                12.4.1. Hospitals and Clinics
                12.4.2. Clinical Research Laboratories
                12.4.3. Academic Institutes
         12.5. Asia Pacific Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2016–2026
                12.5.1. China
                12.5.2. Japan
                12.5.3. India
                12.5.4. Australia & New Zealand
                12.5.5. Rest of Asia Pacific
         12.6. Asia Pacific Plasma Fractionation Market Attractiveness Analysis
                12.6.1. By Product
                12.6.2. By Application
                12.6.3. By End-user
                12.6.4. Country

    13. Latin America Plasma Fractionation Market Analysis and Forecast
         13.1. Introduction
         13.2. Latin America Plasma Fractionation Market Value Forecast, by Product Type, 2016–2026
                13.2.1. Immunoglobulin
                         13.2.1.1. Intravenous Immunoglobulin
                         13.2.1.2. Subcutaneous Immunoglobulin
                13.2.2. Coagulation Factor Concentrates
                         13.2.2.1. Factor VIII
                         13.2.2.2. Factor IX
                         13.2.2.3. Factor XIII
                         13.2.2.4. Prothrombin Complex Concentrates
                         13.2.2.5. Von Willebrand Factor (VWF)
                         13.2.2.6. Fibrinogen Concentrates
                13.2.3. Albumin
                13.2.4. Protease Inhibitors
                13.2.5. Other Plasma Products
         13.3. Latin America Plasma Fractionation Market Value Forecast, by Application, 2016–2026
                13.3.1. Neurology
                13.3.2. Immunology
                13.3.3. Hematology
                13.3.4. Critical Care
                13.3.5. Pulmonology
                13.3.6. Other Applications
         13.4. Latin America Plasma Fractionation Market Value Forecast, by End-user, 2016–2026
                13.4.1. Hospitals and Clinics
                13.4.2. Clinical Research Laboratories
                13.4.3. Academic Institutes
         13.5. Latin America Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2016–2026
                13.5.1. Brazil
                13.5.2. Mexico
                13.5.3. Rest of Latin America
         13.6. Latin America Plasma Fractionation Market Attractiveness Analysis
                13.6.1. By Product
                13.6.2. By Application
                13.6.3. By End-user
                13.6.4. Country

    14. Middle East & Africa Plasma Fractionation Market Analysis and Forecast
         14.1. Introduction
         14.2. Middle East & Africa Plasma Fractionation Market Value Forecast, by Product Type, 2016–2026
                14.2.1. Immunoglobulin
                         14.2.1.1. Intravenous Immunoglobulin
                         14.2.1.2. Subcutaneous Immunoglobulin
                14.2.2. Coagulation Factor Concentrates
                         14.2.2.1. Factor VIII
                         14.2.2.2. Factor IX
                         14.2.2.3. Factor XIII
                         14.2.2.4. Prothrombin Complex Concentrates
                         14.2.2.5. Von Willebrand Factor (VWF)
                         14.2.2.6. Fibrinogen Concentrates
                14.2.3. Albumin
                14.2.4. Protease Inhibitors
                14.2.5. Other Plasma Products
         14.3. Middle East & Africa Plasma Fractionation Market Value Forecast, by Application, 2016–2026
                14.3.1. Neurology
                14.3.2. Immunology
                14.3.3. Hematology
                14.3.4. Critical Care
                14.3.5. Pulmonology
                14.3.6. Other Applications
         14.4. Middle East & Africa Plasma Fractionation Market Value Forecast, by End-user, 2016–2026
                14.4.1. Hospitals and Clinics
                14.4.2. Clinical Research Laboratories
                14.4.3. Academic Institutes
         14.5. Middle East & Africa Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2016–2026
                14.5.1. GCC Countries
                14.5.2. South Africa
                14.5.3. Rest of Middle East & Africa
         14.6. Middle East & Africa Plasma Fractionation Market Attractiveness Analysis
                14.6.1. By Product
                14.6.2. By Application
                14.6.3. By End-user
                14.6.4. Country

    15. Competition Landscape
         15.1. Market Player – Competition Matrix (By Tier and Size of companies)
         15.2. Company Profiles
                15.2.1. CSL Limited
                         15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.2.1.2. Financial Overview
                         15.2.1.3. Product Portfolio
                         15.2.1.4. SWOT Analysis
                         15.2.1.5. Strategic Overview
                15.2.2. Shire plc
                         15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.2.2.2. Financial Overview
                         15.2.2.3. Product Portfolio
                         15.2.2.4. SWOT Analysis
                         15.2.2.5. Strategic Overview
                15.2.3. Sanquin
                         15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.2.3.2. Financial Overview
                         15.2.3.3. Product Portfolio
                         15.2.3.4. SWOT Analysis
                         15.2.3.5. Strategic Overview
                15.2.4. Biotest AG.
                         15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.2.4.2. Financial Overview
                         15.2.4.3. Product Portfolio
                         15.2.4.4. SWOT Analysis
                         15.2.4.5. Strategic Overview
                15.2.5. GRIFOLS
                         15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.2.5.2. Financial Overview
                         15.2.5.3. Product Portfolio
                         15.2.5.4. SWOT Analysis
                         15.2.5.5. Strategic Overview
                15.2.6. Baxter International Inc.
                         15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.2.6.2. Financial Overview
                         15.2.6.3. Product Portfolio
                         15.2.6.4. SWOT Analysis
                         15.2.6.5. Strategic Overview
                15.2.7. Kedrion
                         15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.2.7.2. Financial Overview
                         15.2.7.3. Product Portfolio
                         15.2.7.4. SWOT Analysis
                         15.2.7.5. Strategic Overview
                15.2.8. Octapharma
                         15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.2.8.2. Financial Overview
                         15.2.8.3. Product Portfolio
                         15.2.8.4. SWOT Analysis
                         15.2.8.5. Strategic Overview
                15.2.9. China Biologic Products Holdings, Inc.
                         15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.2.9.2. Financial Overview
                         15.2.9.3. Product Portfolio
                         15.2.9.4. SWOT Analysis
                         15.2.9.5. Strategic Overview

    List of Tables

    Table 01: Plasma Proteins for Clinical Use
    Table 02: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Product Type, 2016–2026
    Table 03: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Immunoglobulin, 2016–2026
    Table 04: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast, Coagulation Factor Concentrates, 2016–2026
    Table 05: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Application, 2016–2026
    Table 06: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
    Table 07: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Region, 2016–2026
    Table 08 : North America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Country, 2016–2026
    Table 09: North America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Product Type, 2016–2026
    Table 10: North America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Immunoglobulin, 2016–2026
    Table 11: North America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Coagulation Factor Concentrates, 2016–2026
    Table 12: North America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Application, 2016–2026
    Table 13: North America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
    Table 14: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 15: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Product Type, 2016–2026
    Table 16: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Immunoglobulin, 2016–2026
    Table 17: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Coagulation Factor Concentrates, 2016–2026
    Table 18: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Application, 2016–2026
    Table 19: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
    Table 20: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 21: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Product Type, 2016–2026
    Table 22: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Immunoglobulin, 2016–2026
    Table 23: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Coagulation Factor Concentrates, 2016–2026
    Table 24: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Application, 2016–2026
    Table 25: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
    Table 26: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 27: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Product Type, 2016–2026
    Table 28: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Immunoglobulin, 2016–2026
    Table 29: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Coagulation Factor Concentrates, 2016–2026
    Table 30: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Application, 2016–2026
    Table 31: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026
    Table 32: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 33: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Product Type, 2016–2026
    Table 34: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Immunoglobulin, 2016–2026
    Table 35: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Coagulation Factor Concentrates, 2016–2026
    Table 36: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast, by Application, 2016–2026
    Table 37: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast, by End-user, 2016–2026

    List of Figures

    Figure 01: Global Plasma Fractionation Market Size (US$ Mn) and Distribution (%), by Region, 2018 and 2026
    Figure 02: Global Plasma Fractionation Market Value Share, by Product Type (2017)
    Figure 03: Global Plasma Fractionation Market Value Share, by Application (2017)
    Figure 04: Global Plasma Fractionation Market Value Share, by Region (2017)
    Figure 05: Opportunity Map, 2017
    Figure 06: Plasma Fractionation Market Size (US$ Mn) Forecast, 2018–2026
    Figure 07: Regional Distribution of Fractionation Plants
    Figure 08: Regional Distribution of Fractionation Throughput
    Figure 09: Worldwide IVIG Unit Sales by Region
    Figure 10: Worldwide Albumin Unit Sales by Region
    Figure 11: Global Plasma Fractionation Market Value Share (%), by Product Type, 2018 and 2026
    Figure 12: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Immunoglobulin
    Figure 13: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Coagulation Factor Concentrates
    Figure 14: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Albumin
    Figure 15: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Protease Inhibitors
    Figure 16: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Other Plasma Products
    Figure 17: Global Plasma Fractionation Market Attractiveness, by Product Type, 2018–2026
    Figure 18: Global Plasma Fractionation Market Value Share (%), by Application, 2018 and 2026
    Figure 19: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Neurology
    Figure 20: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Immunology
    Figure 21: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hematology
    Figure 22: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Critical Care
    Figure23: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Pulmonology
    Figure 24: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Other Applications
    Figure 25: Global Plasma Fractionation Market Attractiveness, by Application, 2018–2026
    Figure 26: Global Plasma Fractionation Market Value Share (%), by End-user, 2018 and 2026
    Figure 27: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals & Clinics
    Figure28: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%)   Projection, Clinical Research Laboratories
    Figure 29: Global Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Academic Institutes
    Figure 30: Global Plasma Fractionation Market Attractiveness, by End-user, 2018–2026
    Figure 31: Global Plasma Fractionation Market Value Share (%), by Region, 2018 and 2026
    Figure 32: Global Plasma Fractionation Market Attractiveness, by Region, 2018–2026
    Figure 33: North America Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 34: North America Plasma Fractionation Market Value Share (%), by Country, 2018 and 2026
    Figure 35: North America Plasma Fractionation Market Attractiveness, by Country, 2018–2026
    Figure 36: North America Plasma Fractionation Market Value Share (%), by Product Type, 2018 and 2026
    Figure 37: North America Plasma Fractionation Market Attractiveness, by Product Type, 2018–2026
    Figure 38: North America Plasma Fractionation Market Value Share (%), by Application, 2018 and 2026
    Figure 39: North America Plasma Fractionation Market Attractiveness, by Application, 2018–2026
    Figure 40: North America Plasma Fractionation Market Value Share (%), by End-user, 2018 and 2026
    Figure 41: North America Plasma Fractionation Market Attractiveness, by End-user, 2018–2026
    Figure 42: Europe Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 43: Europe Plasma Fractionation Market Value Share (%), by Country/Sub-region, 2018 and 2026
    Figure 44: Europe Plasma Fractionation Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 45: Europe Plasma Fractionation Market Value Share (%), by Product Type, 2018 and 2026
    Figure 46: Europe Plasma Fractionation Market Attractiveness, by Product Type, 2018–2026
    Figure 47: Europe Plasma Fractionation Market Value Share (%), by Application, 2018 and 2026
    Figure 48: Europe Plasma Fractionation Market Attractiveness, by Application, 2018–2026
    Figure 49: Europe Plasma Fractionation Market Value Share (%), by End-user, 2018 and 2026
    Figure 50: Europe Plasma Fractionation Market Attractiveness, by End-user, 2018–2026
    Figure 51: Asia Pacific Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 52: Asia Pacific Plasma Fractionation Market Value Share (%), by Country/Sub-region, 2018 and 2026
    Figure 53: Asia Pacific Plasma Fractionation Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 54: Asia Pacific Plasma Fractionation Market Value Share (%), by Product Type, 2018 and 2026
    Figure 55: Asia Pacific Plasma Fractionation Market Attractiveness, by Product Type, 2018–2026
    Figure 56: Asia Pacific Plasma Fractionation Market Value Share (%), by Application, 2018 and 2026
    Figure 57: Asia Pacific Plasma Fractionation Market Attractiveness, by Application, 2018–2026
    Figure 58: Asia Pacific Plasma Fractionation Market Value Share (%), by End-user, 2018 and 2026
    Figure 59: Asia Pacific Plasma Fractionation Market Attractiveness, by End-user, 2018–2026
    Figure 60: Latin America Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 61: Latin America Plasma Fractionation Market Value Share (%), by Country/Sub-region, 2018 and 2026
    Figure 62: Latin America Plasma Fractionation Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 63: Latin America Plasma Fractionation Market Value Share (%), by Product Type, 2018 and 2026
    Figure 64: Latin America Plasma Fractionation Market Attractiveness, by Product Type, 2018–2026
    Figure 65: Latin America Plasma Fractionation Market Value Share (%), by Application, 2018 and 2026
    Figure 66: Latin America Plasma Fractionation Market Attractiveness, by Application, 2018–2026
    Figure 67: Latin America Plasma Fractionation Market Value Share (%), by End-user, 2018 and 2026
    Figure 68: Latin America Plasma Fractionation Market Attractiveness, by End-user, 2018–2026
    Figure 69: Middle East & Africa Plasma Fractionation Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure70: Middle East & Africa Plasma Fractionation Market Value Share (%), by Country/Sub-region, 2018 and 2026
    Figure 71: Middle East & Africa Plasma Fractionation Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 72: Middle East & Africa Plasma Fractionation Market Value Share (%), by Product Type, 2018 and 2026
    Figure 73: Middle East & Africa Plasma Fractionation Market Attractiveness, by Product Type, 2018–2026
    Figure 74: Middle East & Africa Plasma Fractionation Market Value Share (%), by Application, 2018 and 2026
    Figure 75: Middle East & Africa Plasma Fractionation Market Attractiveness, by Application, 2018–2026
    Figure 76: Middle East & Africa Plasma Fractionation Market Value Share (%), by End-user, 2018 and 2026
    Figure 77: Middle East & Africa Plasma Fractionation Market Attractiveness, by End-user, 2018–2026

Copyright © Transparency Market Research, Inc. All Rights reserved